Advancing diagnostics for Chagas disease: key product characteristics and harmonized evaluation strategies - an expert meeting report - Scorecard - MDSpire

Advancing diagnostics for Chagas disease: key product characteristics and harmonized evaluation strategies - an expert meeting report

  • By

  • Laura C. Bohorquez

  • Alejandro G. Schijman

  • Freddy Perez

  • Hector Coto

  • Andrea Marchiol

  • Maria-Jesus Pinazo

  • June 17, 2026

  • 0 min

Share

Clinical Scorecard: Enhancing Chagas Disease Diagnostics: Essential Product Features and Standardized Assessment Approaches - Insights from an Expert Meeting

At a Glance

CategoryDetail
Condition
Key MechanismsInfection caused by Trypanosoma cruzi.
Target Population
Care Setting

Key Highlights

  • Over 10,000 CD-related deaths reported annually.
  • Less than 10% of infected individuals diagnosed.
  • PAHO/WHO recommends serological rapid diagnostic tests for screening.

Guideline-Based Recommendations

Diagnosis

  • Use serological rapid diagnostic tests (RDTs) for screening and research.

Management

  • Initiate antiparasitic treatment soon after infection.

Monitoring & Follow-up

  • Evaluate the performance and economic impact of new diagnostics.

Risks

  • Limited access to diagnostics can hinder timely treatment.

Patient & Prescribing Data

Individuals infected with Trypanosoma cruzi, primarily in Latin America.

Antiparasitic treatment can prevent mother-to-child transmission.

Clinical Best Practices

    Related Resources & Content

    Original Source(s)

    Related Content